Xilio Therapeutics Ownership | Who Owns Xilio Therapeutics?

Xilio Therapeutics Ownership Summary

Xilio Therapeutics is owned by 22.03% institutional investors, 17.58% insiders, and 60.39% retail investors. Gilead sciences is the largest institutional shareholder, holding 14.35% of XLO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.48% of its assets in Xilio Therapeutics shares.

XLO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Xilio Therapeutics	22.03%	17.58%	60.39%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Gilead sciences	9.11M	14.35%	$8.70M
Bain capital life sciences investors	4.57M	7.20%	$4.36M
Rivervest venture management	1.44M	5.16%	$1.37M
Rock springs capital management lp	3.00M	4.73%	$2.87M
Morgan stanley	1.11M	3.99%	$1.05M
Merck	1.48M	2.34%	$1.42M
Takeda pharmaceutical	1.48M	2.32%	$1.42M
Fmr	1.40M	2.20%	$1.33M
Vanguard group	902.53K	1.42%	$861.92K
Geode capital management	358.42K	0.56%	$342.33K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rivervest venture management	1.44M	20.01%	$1.37M
Takeda pharmaceutical	1.48M	5.33%	$1.42M
Gilead sciences	9.11M	0.56%	$8.70M
Merck	1.48M	0.55%	$1.42M
Bain capital life sciences investors	4.57M	0.51%	$4.36M
Rock springs capital management lp	3.00M	0.11%	$2.87M
Trustees of columbia university in the city of new york	249.63K	0.04%	$238.40K
Sevenbridge financial group	41.00K	0.01%	$26.94K
Pinnacle financial group, llc / il	10.00K	0.00%	$9.47K
Bridgeway capital management	71.08K	0.00%	$67.88K

Top Buyers

Holder	Shares	% Assets	Change
Gilead sciences	9.11M	0.56%	9.11M
Merck	1.48M	0.55%	1.48M
Morgan stanley	1.11M	0.00%	890.84K
Trustees of columbia university in the city of new york	249.63K	0.04%	249.63K
Ubs group	249.40K	-	233.67K

Top Sellers

Holder	Shares	% Assets	Change
Atlas venture life science advisors	-	-	-992.91K
Two sigma securities	-	-	-44.45K
Engineers gate manager lp	-	-	-32.75K
Pfg investments	-	-	-30.00K
Prelude capital management	-	-	-29.50K

New Positions

Holder	Shares	% Assets	Change	Value
Gilead sciences	9.11M	0.56%	9.11M	$8.70M
Merck	1.48M	0.55%	1.48M	$1.42M
Trustees of columbia university in the city of new york	249.63K	0.04%	249.63K	$238.40K
Raymond james financial	50.09K	-	50.09K	$47.83K
Susquehanna group, llp	49.09K	-	49.09K	$46.88K

Sold Out

Holder	Change
Qube research	-4.00
Wells fargo & company/mn	-108.00
Royal bank of canada	-533.00
Adar1 capital management	-1.50K
Dunhill financial	-10.27K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	17	-48.48%	13,981,677	-12.36%	22	3.49%	5	-64.29%	4	-
Sep 30, 2024	32	6.67%	14,477,824	11.08%	22	1.05%	14	-12.50%	4	-20.00%
Jun 30, 2024	30	-	13,033,702	18.53%	46	2.93%	16	45.45%	5	-
Mar 31, 2024	30	-6.25%	10,996,048	-26.45%	39	1.35%	11	-8.33%	5	25.00%
Dec 31, 2023	32	3.23%	14,951,160	-5.73%	54	1.63%	12	71.43%	4	-42.86%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	739.56K	1.48%	-
Fidelity Extended Market Index	176.36K	0.34%	-1.12K
Vanguard Institutional Extnd Mkt Idx Tr	160.02K	0.32%	-
Bridgeway Ultra-Small Company Market	71.08K	0.16%	-
iShares Micro-Cap ETF	66.46K	0.13%	-
Fidelity Total Market Index	63.72K	0.12%	-
Fidelity Series Total Market Index	43.22K	0.08%	-
Northern Trust Extended Eq Market Idx	30.97K	0.07%	-
NT Ext Equity Mkt Idx Fd - NL	34.73K	0.07%	27.40K
NT Ext Equity Mkt Idx Fd - L	30.97K	0.06%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jan 02, 2025	Frankenfield Christopher James	Chief Financial Officer	Sell	$6.84K
Jan 02, 2025	Brennan Kevin M.	SVP, FINANCE AND ACCOUNTING	Sell	$1.77K
Dec 18, 2024	GILEAD SCIENCES, INC.	-	Buy	$1.83M
Dec 18, 2024	GILEAD SCIENCES, INC.	-	Buy	$609.28
Apr 02, 2024	GILEAD SCIENCES, INC.	-	Buy	$368.79K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	2
2024 Q4	2	-
2024 Q3	-	-
2024 Q2	2	-
2024 Q1	-	6

XLO Ownership FAQ

Who Owns Xilio Therapeutics?

Xilio Therapeutics shareholders are primarily institutional investors at 22.03%, followed by 17.58% insiders and 60.39% retail investors. The average institutional ownership in Xilio Therapeutics's industry, Biotech Stocks , is 68.48%, which Xilio Therapeutics falls below.

Who owns the most shares of Xilio Therapeutics?

Xilio Therapeutics’s largest shareholders are Gilead sciences (9.11M shares, 14.35%), Bain capital life sciences investors (4.57M shares, 7.20%), and Rivervest venture management (1.44M shares, 5.16%). Together, they hold 26.71% of Xilio Therapeutics’s total shares outstanding.

Does Blackrock own Xilio Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Xilio Therapeutics.

Who is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested?

Rivervest venture management is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.01% of its assets in 1.44M Xilio Therapeutics shares, valued at 1.37M$.

Who is the top mutual fund holder of Xilio Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Xilio Therapeutics shares, with 1.48% of its total shares outstanding invested in 739.56K Xilio Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools